دورية أكاديمية
Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers.
| العنوان: | Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers. |
|---|---|
| المؤلفون: | Espinosa ML; Department of Dermatology, University of Chicago Pritzker School of Medicine, Chicago, IL, United States., Abad C; Department of Dermatology, City of Hope Los Angeles, Duarte, CA, United States., Kurtzman Y; Department of Dermatology, City of Hope Los Angeles, Duarte, CA, United States., Abdulla FR; Department of Dermatology, City of Hope Los Angeles, Duarte, CA, United States. |
| المصدر: | Frontiers in oncology [Front Oncol] 2021 May 27; Vol. 11, pp. 605941. Date of Electronic Publication: 2021 May 27 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Treatment of head and neck cancers requires multidisciplinary collaboration to reduce morbidity and mortality associated with the tumor burden, as well as to preserve function of organs and structures. With the use of various new targeted therapies come new adverse events including dermatologic toxicities, which may consist of xerosis, nail and hair changes, morbilliform or papulopustular rashes, to more severe eruptions such as Stevens-Johnson syndrome. We describe the dermatologic toxicities and corresponding grades of severity and associated pathophysiology resulting from seven therapeutics used to treat head and neck cancers: cetuximab, trastuzumab, pembrolizumab, nivolumab, lentatinib, larotrectinib, and entrectinib. Being familiar with these dermatologic toxicities allows clinicians to provide comprehensive counseling for patients, encourage preventative measures, and to know when it is appropriate to hold therapy or permanently stop treatment. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Espinosa, Abad, Kurtzman and Abdulla.) |
| References: | Acta Derm Venereol. 2008;88(1):84-6. (PMID: 18176767) Lancet Oncol. 2012 Feb;13(2):135-44. (PMID: 22257523) J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. (PMID: 32360716) Eur J Cancer. 2007 Mar;43(5):845-51. (PMID: 17289377) Future Oncol. 2019 Mar;15(7):717-726. (PMID: 30638399) Clin Cosmet Investig Dermatol. 2017 Sep 11;10:353-361. (PMID: 28932126) Oncology. 2014;86(4):212-29. (PMID: 24820548) Oxf Med Case Reports. 2019 Mar 29;2019(3):omz016. (PMID: 30949354) Clin Rev Allergy Immunol. 2007 Oct;33(1-2):67-77. (PMID: 18094948) Eur J Cancer. 2016 Jun;60:12-25. (PMID: 27043866) Expert Opin Emerg Drugs. 2018 Dec;23(4):283-299. (PMID: 30376740) J Oncol. 2009;2009:567486. (PMID: 19424511) JAMA Dermatol. 2016 Jan;152(1):45-51. (PMID: 26501224) N Engl J Med. 2016 Nov 10;375(19):1856-1867. (PMID: 27718784) JAMA Dermatol. 2015 Nov;151(11):1206-1212. (PMID: 26222619) Cancer Immunol Res. 2016 May;4(5):383-9. (PMID: 26928461) Am J Pathol. 2003 Jul;163(1):303-12. (PMID: 12819035) Ann Oncol. 2001;12 Suppl 1:S9-13. (PMID: 11521729) CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):230-239. (PMID: 30681293) Cell Mol Life Sci. 2008 May;65(10):1566-84. (PMID: 18259690) Radiat Oncol. 2006 May 02;1:11. (PMID: 16722544) J Clin Oncol. 2015 Jun 10;33(17):1974-82. (PMID: 25605845) Lancet Oncol. 2020 Feb;21(2):271-282. (PMID: 31838007) Int J Cancer. 2008 Feb 1;122(3):664-71. (PMID: 17943726) Science. 2013 Mar 29;339(6127):1546-58. (PMID: 23539594) Curr Probl Cancer. 2017 Mar - Apr;41(2):125-128. (PMID: 28190531) J Cutan Pathol. 2017 Feb;44(2):158-176. (PMID: 27859479) J Am Acad Dermatol. 2012 Nov;67(5):e201-2. (PMID: 23062912) Postepy Dermatol Alergol. 2017 Oct;34(5):418-428. (PMID: 29507555) J Am Acad Dermatol. 2020 Nov;83(5):1415-1424. (PMID: 32320766) Biochim Biophys Acta. 2016 Jan;1865(1):58-71. (PMID: 26432723) Head Neck. 2018 Apr;40(4):676-686. (PMID: 29171929) JAMA Dermatol. 2016 Oct 1;152(10):1128-1136. (PMID: 27411054) J Immunother. 2012 Feb-Mar;35(2):169-78. (PMID: 22306905) J Cutan Pathol. 2016 Aug;43(8):688-96. (PMID: 27086658) Onco Targets Ther. 2020 Apr 09;13:3047-3059. (PMID: 32308436) Lancet Oncol. 2017 May;18(5):654-662. (PMID: 28314691) Dermatoendocrinol. 2011 Jan;3(1):32-6. (PMID: 21519407) Am J Clin Oncol. 2016 Aug;39(4):407-15. (PMID: 27077276) J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. (PMID: 30865922) Case Rep Dermatol. 2018 Aug 9;10(2):190-197. (PMID: 30186132) Ann Oncol. 2021 Jun;32(6):736-745. (PMID: 33667669) J Invest Dermatol. 2003 Dec;121(6):1515-21. (PMID: 14675204) J Am Acad Dermatol. 2020 Apr;82(4):998-1000. (PMID: 31604105) J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20. (PMID: 25592338) Cancer. 2016 Apr 1;122(7):1097-107. (PMID: 26784937) J Investig Med High Impact Case Rep. 2016 Oct 25;4(4):2324709616674316. (PMID: 27826593) Clin J Oncol Nurs. 2008 Apr;12(2):283-90. (PMID: 18390464) N Engl J Med. 2018 Feb 22;378(8):731-739. (PMID: 29466156) J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. (PMID: 32454097) Ann Oncol. 2001;12 Suppl 1:S3-8. (PMID: 11521719) Cancer Sci. 2015 Dec;106(12):1714-21. (PMID: 26426092) Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945) J Am Acad Dermatol. 2019 Apr;80(4):990-997. (PMID: 30399387) Oral Oncol. 2019 Apr;91:129-131. (PMID: 30773349) Clin Oncol (R Coll Radiol). 2012 Feb;24(1):80-1. (PMID: 22019483) JAMA Dermatol. 2016 May 1;152(5):590-2. (PMID: 26675815) Oncologist. 2018 Oct;23(10):1119-1126. (PMID: 30018132) Oral Oncol. 2018 Jun;81:45-51. (PMID: 29884413) Support Care Cancer. 2011 Aug;19(8):1079-95. (PMID: 21630130) J Med Chem. 2016 Apr 14;59(7):3392-408. (PMID: 27003761) Asia Pac J Clin Oncol. 2018 Feb;14(1):23-31. (PMID: 28464435) Nat Commun. 2014 Sep 10;5:4846. (PMID: 25204415) N Engl J Med. 2015 Feb 12;372(7):621-30. (PMID: 25671254) Biologics. 2013;7:77-90. (PMID: 23723688) Clin Breast Cancer. 2015 Feb;15(1):e77-81. (PMID: 25445421) J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. (PMID: 30025829) Future Oncol. 2015;11(17):2471-84. (PMID: 26274495) J Am Acad Dermatol. 2020 Sep;83(3):955-957. (PMID: 32014533) Am Fam Physician. 2017 Jul 1;96(1):44-51. (PMID: 28671378) Case Rep Oncol. 2011 Apr 11;4(1):229-35. (PMID: 21537373) Semin Oncol. 2019 Feb;46(1):57-64. (PMID: 30685073) J Clin Invest. 2018 Mar 1;128(3):985-996. (PMID: 29400697) Oncologist. 2005 May;10(5):345-56. (PMID: 15851793) J Am Acad Dermatol. 2017 May;76(5):879-888. (PMID: 28216034) J Am Acad Dermatol. 2020 Jul;83(1):46-52. (PMID: 32179082) Clin Cancer Res. 2008 Sep 1;14(17):5459-65. (PMID: 18765537) J Otolaryngol Head Neck Surg. 2017 Apr 4;46(1):29. (PMID: 28376866) Target Oncol. 2010 Dec;5(4):295-6. (PMID: 20949375) Curr Opin Oncol. 2016 Jul;28(4):254-63. (PMID: 27136138) Nat Rev Clin Oncol. 2017 Jul;14(7):397-398. (PMID: 28397825) JAMA Dermatol. 2017 Jun 1;153(6):603-605. (PMID: 28355425) J Dermatol. 2017 Jan;44(1):99-100. (PMID: 27177467) Yale J Biol Med. 2020 Mar 27;93(1):123-132. (PMID: 32226342) Am J Ther. 2019 Sep/Oct;26(5):e647-e649. (PMID: 30239341) J Natl Compr Canc Netw. 2009 May;7 Suppl 1:S5-21; quiz S22-4. (PMID: 19470276) Fundam Clin Pharmacol. 2020 Dec;34(6):736-742. (PMID: 32246859) J Immunother. 2016 Jun;39(5):202-4. (PMID: 27163740) J Eur Acad Dermatol Venereol. 2017 May;31(5):e254-e257. (PMID: 27739129) J Clin Oncol. 2012 May 10;30(14):1594-600. (PMID: 22393084) J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. (PMID: 26793994) Clin Cancer Res. 2016 Jan 1;22(1):44-53. (PMID: 26311725) J Invest Dermatol. 2008 Jun;128(6):1365-74. (PMID: 18049451) J Clin Oncol. 2010 Mar 10;28(8):1351-7. (PMID: 20142600) |
| فهرسة مساهمة: | Keywords: adverse event; cetuximab; dermatologic toxicity; head and neck cancer; immunotherapy; nivolumab; pembrolizumab; trastuzumab |
| تواريخ الأحداث: | Date Created: 20210614 Latest Revision: 20210615 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8190330 |
| DOI: | 10.3389/fonc.2021.605941 |
| PMID: | 34123780 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2021.605941 |